MICHAEL R MIGDEN to Smoothened Receptor
This is a "connection" page, showing publications MICHAEL R MIGDEN has written about Smoothened Receptor.
Connection Strength
0.356
-
Phase I Study of LY2940680, a Smo Antagonist, in Patients with Advanced Cancer Including Treatment-Na?ve and Previously Treated Basal Cell Carcinoma. Clin Cancer Res. 2018 05 01; 24(9):2082-2091.
Score: 0.154
-
Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update. Future Oncol. 2016 Sep; 12(18):2095-105.
Score: 0.137
-
The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. J Am Acad Dermatol. 2016 Jul; 75(1):113-125.e5.
Score: 0.034
-
Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma. Cancer Cell. 2015 Mar 09; 27(3):327-41.
Score: 0.031